A subgroup analysis of female patients in a phase 3 open-label study to assess the safety and efficacy of pegunigalsidase alfa in patients with fabry disease previously treated with agalsidase alfa

Authors
Category Primary study
JournalNephrology Dialysis Transplantation
Year 2021
This article has no abstract
Epistemonikos ID: bfcc595a5f08bfa89d0992c41fcc80247a1020e5
First added on: Feb 13, 2025